Novo Nordisk A/S: Share repurchase programme

December 05, 2011 08:06 ET | Source: Novo Nordisk A/S Novo Nordisk A/S

For release content, please refer to the attachment.

Attachments

Company Announcement no 76 / 2011

Company Announcement no 76 / 2011...

Recommended Reading

December 22, 2025 17:50 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

FDA has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term
Read More
December 12, 2025 08:57 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Read More